The very slow progress in the treatment of severe diseases has led to the adoption of a multidisciplinary approach to the targeted delivery and release of drugs, underpinned by nanoscience and...
http://www.azonano.com/article.aspx?ArticleID=1702 | 23 Aug 2006
Lumiphore Inc., a portfolio company of Nanostart
AG, has signed a global cooperation with Algeta ASA (Oslo Stock Exchange,
ticker: ALGETA), a leading company specializing in innovative...
http://www.azonano.com/news.aspx?newsID=20185 | 26 Oct 2010
An international team of physicists at Los Alamos National Laboratory has
succeeded in using intense laser light to accelerate protons to energies never
before achieved. Using this technique,...
http://www.azonano.com/news.aspx?newsID=14447 | 2 Nov 2009
Radioactive elements, or radionuclides, are well-established anticancer agents whose main limitation is that they kill healthy cells almost as easily as they do tumors. But because nanoparticles...
http://www.azonano.com/news.aspx?newsID=4788 | 23 Aug 2007
New piece of medical technology unveiled at the National
Physical Laboratory (NPL) today will help improve the success rates of radiotherapy
cancer treatments. The new clinical electron...
http://www.azonano.com/news.aspx?newsID=8697 | 15 Nov 2008
Nanobiotix, an emerging
nanomedicine company, announced today exciting preclinical results using its
patented nanoXray therapeutics platform to fight tumors. The preclinical study,...
http://www.azonano.com/news.aspx?newsID=11556 | 18 May 2009
NANOBIOTIX, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive Phase I interim results of its lead nanoparticle-based product,...
http://www.azonano.com/news.aspx?newsID=27524 | 4 Jun 2013
NANOBIOTIX, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that its lead compound NBTXR3 has received authorization from the...
http://www.azonano.com/news.aspx?newsID=27607 | 14 Jun 2013
MagForce AG / MagForce AG Receives BfArM Approval to Start the Post-Marketing Study in Glioblastoma with NanoTherm® Therapy.
Processed and transmitted by Thomson Reuters ONE.
http://www.azonano.com/news.aspx?newsID=27045 | 9 Apr 2013
Scientists at Queen's University Belfast have shown that they can deliver a gene directly into breast cancer cells causing them to self-destruct, using an innovative, miniscule gene transport system,...
http://www.azonano.com/news.aspx?newsID=21788 | 1 Mar 2011